CYP2J2 Antibody

Code CSB-PA001968
Size US$100
Order now
Image
  • Western Blot analysis of various cells using CYP2J2 Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CYP2J2
Alternative Names
Arachidonic acid epoxygenase antibody; CP2J2_HUMAN antibody; CPJ2 antibody; CYP2J2 antibody; CYPIIJ2 antibody; Cytochrome P450 2J2 antibody; Cytochrome P450 family 2 subfamily J polypeptide 2 antibody; Cytochrome P450 subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2 antibody; Cytochrome P450 subfamily IIJ polypeptide 2 antibody; Flavoprotein linked monooxygenase antibody; Microsomal monooxygenase antibody; OTTHUMP00000010550 antibody
Raised in
Rabbit
Species Reactivity
Human,Monkey
Immunogen
Synthesized peptide derived from the Internal region of Human CYP2J2.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, IHC, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:10000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) in the cardiovascular system. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of PUFA. Converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EpETrE), likely playing a major role in the epoxidation of endogenous cardiac arachidonic acid pools. In endothelial cells, participates in eicosanoids metabolism by converting hydroperoxide species into hydroxy epoxy metabolites. In combination with 15-lipoxygenase metabolizes arachidonic acid and converts hydroperoxyicosatetraenoates (HpETEs) into hydroxy epoxy eicosatrienoates (HEETs), which are precursors of vasodilatory trihydroxyicosatrienoic acids (THETAs). This hydroperoxide isomerase activity is NADPH- and O2-independent. Catalyzes the monooxygenation of a various xenobiotics, such as danazol, amiodarone, terfenadine, astemizole, thioridazine, tamoxifen, cyclosporin A and nabumetone. Catalyzes hydroxylation of the anthelmintics albendazole and fenbendazole. Catalyzes the sulfoxidation of fenbedazole.
Gene References into Functions
  1. Cell survival decreases with ROS exposure when CYP2J2 is chemically inhibited. PMID: 29343610
  2. Data show the importance of the formation of a hydrogen bond between cytochrome P450 2J2 arginine 117 (R117) and the keto group of the substrates. PMID: 30012976
  3. these data can aid the design of other analogues that have reduced cardiotoxicity, which do not modulate CYP2J2's arachidonic acid metabolism. PMID: 29629756
  4. demonstrate that doxorubicin (DOX) and 7-de-aDOX inhibit CYP2J2-mediated AA metabolism and 7-de-aDOX binds close to the active site to alter the ratio of cardioprotective epoxyeicosatrienoic acids. PMID: 29200270
  5. The use of LKY-047 as a selective CYP2J2 inhibitor. PMID: 28461575
  6. a computational investigation of the binding of arachidonic acid (AA) to CYP2J2 using homology modelling, induced fit docking (IFD) and molecular dynamics (MD) simulations. PMID: 27796781
  7. Study found a significant interaction between CYP2J2- rs890293 and PPAR -gamma- rs1805192 and participants with GT or TT of rs890293 and CG or GG of rs1805192 genotype have the highest late-onset Alzheimer's disease risk, compared to participants with GG of rs890293 and CC of rs1805192 genotype. PMID: 27396818
  8. dysregulation of the CYP epoxyeicosanoid pathway is a key pathological consequence of NASH PMID: 27401401
  9. CYP2J2 is widely expressed in tissues, especially heart, vascular smooth muscle, salivary glands and placenta. Recent studies have shown that overexpression of CYP2J2 in vivo reverses several pathological processes in animals, including hypertension and other cardiovascular pathologies and insulin resistance. PMID: 27286171
  10. Homocysteine (Hcy) facilitated cytochrome P-450 CYP2J2 (CYP2J2) upregulation in hepatocellular carcinoma (HCC) cells by DNA demethylation. PMID: 28030819
  11. Endothelial overexpression of CYP2J2 significantly changed oxylipin profiles. PMID: 28328948
  12. MAPK signaling pathway was involved in the up-regulation of CYP2J2 levels by glutamate in U251 cells. PMID: 28237619
  13. -50G/T polymorphism might be a risk factor for ischemic stroke in Chinese population PMID: 28272236
  14. Data show that CYP2J2 gene delivery reduced vessel wall thickening. PMID: 27459385
  15. Data suggest that antiarrhythmic prodrugs amiodarone and dronedarone are extensively metabolized by CYP2J2; specific CYP2J2 metabolites include N-desbutyldronedarone and N-desethylamiodarone, potent [reversible/irreversible] inhibitors of CYP2J2. PMID: 26972388
  16. Tanshinone IIA exerts its anticancer effect by inhibiting CYP2J2 activity in HepG2 cells. PMID: 26209360
  17. CYP2J2 expression showed significant upregulation (P<0.05) during Cy treatment before stem cell transplantation PMID: 25601761
  18. Here we present the detection of substrate binding to cytochrome P450-2J2 (CYP2J2), the predominant P450 in the human heart, using a combination of Nanodisc technology and a nanohole plasmonic sensor PMID: 26334592
  19. Our results suggest that individuals with any conventional risk factor for MI along with CYP2J2*7 variant allele may be predisposed to risk of myocardial infarct in South Indian population PMID: 25560582
  20. CYP2J2 and EETs prevent cardiac fibrosis and cardiac dysfunction by suppressing transmission of pro-inflammation from cardiomyocytes to macrophages in heart PMID: 25686540
  21. findings can give a structural mechanism for the mutation-induced dysfunction in the CYP2J2-mediated arachidonic acid metabolism. PMID: 25204827
  22. The CYP2J2 rs890293 T allele and GT+TT genotype were significantly associated with an increased risk of late onset Alzheimer disease. PMID: 25796175
  23. Data suggest that up-regulation of CYP2J2 activity can attenuate type 2 diabetes and improve insulin resistance via down-regulation of NFkappaB and MAPK signaling pathways and up-regulation of PPARgamma. PMID: 25389363
  24. CYP2J2 mediates bacterial phagocytosis in macrophages, and implicates a defect in the CYP2J2 pathway may regulate bacterial clearance in Crohn's disease. PMID: 24058654
  25. Established and emerging roles of CYP2J2 in the biology of vascular endothelial cells. [Review] PMID: 23474289
  26. CYP2J2 activity in the cell line was inhibited by danazol. PMID: 24021950
  27. These findings demonstrate that Cyp2j gene products regulate the pulmonary vascular response to hypoxia PMID: 24278032
  28. CYP2J2 overexpression only moderately reduced transverse aortic constriction-induced cardiac hypertrophy and did not affect the hypertrophic response to beta-adrenergic stimulation. PMID: 24023684
  29. The aim of the present study was to assess the association between the human CYP2J2 gene polymorphism and coronary artery disease (CAD) in a Han and Uygur population of China. PMID: 23684773
  30. Compared the effects of N-terminal modifications on the properties of CYP2J2 with respect to the activity of the protein in model lipid bilayers using Nanodiscs. PMID: 23661295
  31. N404Y mutation could reposition the side-chain of Leu(378), making it no longer form a hydrogen bond with the carboxyl group of arachidonic acid. PMID: 23647230
  32. Data indicate that cardiac-specific overexpression of arachidonate epoxygenase (CYP2J2) significantly protects against diabetic cardiomyopathy, which may be due to improved cardiac insulin resistance, glucose uptake, and reversal of cardiac hypertrophy. PMID: 23696562
  33. High CYP2J2 expression is associated with cancer. PMID: 22761738
  34. uteroplacental CYP2J2 overexpression contributes to preeclampsia. PMID: 23155181
  35. This study provides evidence of potential association of CYP2J2*7 polymorphism with hypertension in the Saudi population with or without diabetes and obesity. PMID: 22731644
  36. No association has been found between the CYP2J2 (rs890293, -76G > T) or CYP2S1 (rs34971233, 13106C > T, P466L and rs338583, 13255A > G) gene polymorphisms and respiratory diseases. PMID: 22232929
  37. This case-control study as well as meta-analysis suggested no association between CYP2J2 G-50T and EPHX2 R287Q and the risk of developing coronary artery disease PMID: 21642892
  38. CYP2J2 overexpression in cultured human-derived malignant hematologic cell lines markedly accelerated proliferation and attenuated apoptosis PMID: 21030485
  39. Haplotypes of CYP2J2 are associated with myocardial infarction in a Chinese Han population. PMID: 20597138
  40. Age of onset, family history, and obesity may modify typ3 2 diabetes polymorphism in younger onset typ32 diabetees. PMID: 20140850
  41. The data indicate that epoxygenase 2J2 gene polymorphism is not a risk factor of acute coronary syndrome in Ukrainian population. PMID: 20480811
  42. eight novel substrates for CP2J were identified that vary in size and overall topology; data suggest that CYP2J2 may be an unrecognized participant in first-pass metabolism, but its contribution is minor relative to that of CYP3A4 PMID: 19923256
  43. data do not support a major role for the CYP2J2 -50G>T variant in determining blood pressure level and incident ischemic events PMID: 19851119
  44. CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo PMID: 19823578
  45. expression levels of the immunoreactive protein with the CYP2J2 antibody in the small intestine were well correlated with the activities of the astemizole O-demethylation PMID: 12386130
  46. role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia PMID: 12737630
  47. The CYP2J2*6 allele is rare in the Caucasian population, and no association is inferred between this allelic variant and type 1 or type 2 diabetic complications. PMID: 14575523
  48. Transgenic mice overexpressing human CYP2J2 have improved postischemic recovery of left ventricular function. PMID: 15256482
  49. Overexpressoin of CYP2J2 in transgenic mice increases l-type calcium channles in cardiomyocytes. PMID: 15361551
  50. a functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary artery disease PMID: 15466638

Show More

Hide All

Subcellular Location
Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Protein Families
Cytochrome P450 family
Tissue Specificity
Highly expressed in heart, present at lower levels in liver, kidney and skeletal muscle (at protein level).
Database Links

HGNC: 2634

OMIM: 601258

KEGG: hsa:1573

STRING: 9606.ENSP00000360247

UniGene: Hs.152096

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*